Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
暂无分享,去创建一个
R. Advani | J. Connors | K. Savage | J. Radford | S. Ansell | P. Zinzani | P. Smolewski | A. Younes | N. Bartlett | W. Kim | Á. Illés | A. Gallamini | M. Hutchings | M. Picardi | J. Walewski | R. Ramchandren | H. Lee | M. Fanale | E. Lech-Maranda | D. Straus | T. Feldman | M. Długosz-Danecka | Rachael Liu | Sergey M. Alekseev | K. Fenton | J. Muñoz | M. Little
[1] R. Bouabdallah,et al. PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study , 2020 .
[2] J. Connors,et al. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy , 2020, Leukemia & lymphoma.
[3] O. Casasnovas,et al. Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials , 2020, Cancer medicine.
[4] R. Advani,et al. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] I. Flinn,et al. Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress). , 2020 .
[6] J. Friedberg,et al. An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. , 2020 .
[7] R. Advani,et al. Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. , 2019, Blood.
[8] Sonali M. Smith,et al. Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. , 2019, Blood.
[9] R. Bouabdallah,et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. , 2019, The Lancet. Oncology.
[10] N. Kalakonda,et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial , 2018, The Lancet. Oncology.
[11] A. Shimoni,et al. Second Malignancies after Hematopoietic Stem Cell Transplantation , 2018, Current Treatment Options in Oncology.
[12] A. Rossi,et al. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Greil,et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.
[14] J. Connors,et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.
[15] M. Sydes,et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials , 2017, Haematologica.
[16] J. Radford,et al. RESPONSE‐ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE‐ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). , 2017 .
[17] R. Gascoyne,et al. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. d'Amore,et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.
[19] J. Auger,et al. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. , 2014, Fertility and sterility.
[20] V. Diehl,et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. , 2013, Journal of Clinical Oncology.
[21] J. Armitage,et al. Positron emission tomographic scans in lymphoma: convention and controversy. , 2012, Mayo Clinic proceedings.
[22] Scott E. Smith,et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. , 2012, Blood.
[23] V. Diehl,et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). , 2008, Blood.
[24] P. Hall,et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Diehl,et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Radford,et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records , 1997, BMJ.
[27] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.